Asset Details
Do you wish to reserve the book?
Development of a synthetic Vi polysaccharide vaccine for typhoid fever
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of a synthetic Vi polysaccharide vaccine for typhoid fever
Do you wish to request the book?
Development of a synthetic Vi polysaccharide vaccine for typhoid fever
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development of a synthetic Vi polysaccharide vaccine for typhoid fever
2017
Overview
Typhoid fever remains a serious public health problem with a high impact on toddlers and young children. Vaccines against the Vi capsular polysaccharide are efficacious against typhoid fever demonstrating that antibodies against Vi confer protection. The currently licensed Vi typhoid vaccines have however limited efficacy and are manufactured by a complex process from wild-type bacteria. Due to these inherent issues with the current vaccines, an alternative vaccine based on an O-acetylated high molecular weight (HMW) polygalacturonic acid (GelSite-OAc™) was generated. The HMW polygalacturonic acid shares the same backbone as the Vi polysaccharide of Salmonella Typhi. The GelSite-OAc™ has a high molecular weight (>1 × 106 Da) and a high degree of O-acetylation (DOAc) (>5 μmole/mg), both exceeding the potency specifications of the current Vi vaccine. Studies in Balb/c mice demonstrated that GelSite-OAc™ was highly immunogenic, inducing a strong antigen-specific antibody response in a DOAc- and dose-dependent manner which was comparable to or higher than those induced by the licensed Vi vaccine. Importantly, the GelSite-OAc™ was shown to be fully protective in mice against lethal challenge with Salmonella Typhi. Furthermore, the GelSite-OAc™ demonstrated a boosting effect or memory response, exhibiting a >2-fold increase in antibody levels upon the second immunization with either GelSite-OAc™ or the Vi vaccine. This novel boosting effect is unique among polysaccharide antigens and potentially makes GelSite-OAc™ effective in people under 2 years old. Together these results suggest that the GelSite-OAc™ could be a highly effective vaccine against Salmonella Typhi.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Acids
/ Animals
/ Antibodies, Bacterial - blood
/ Antibody Formation - immunology
/ Antigens
/ bacteria
/ Children
/ Fever
/ Food contamination & poisoning
/ Licenses
/ Mice
/ Pectins - administration & dosage
/ Polysaccharides, Bacterial - administration & dosage
/ Polysaccharides, Bacterial - chemistry
/ Polysaccharides, Bacterial - immunology
/ Proteins
/ Salmonella typhi - immunology
/ toddlers
/ Typhoid
/ Typhoid Fever - microbiology
/ Typhoid Fever - prevention & control
/ Typhoid-Paratyphoid Vaccines - administration & dosage
/ Typhoid-Paratyphoid Vaccines - chemistry
/ Typhoid-Paratyphoid Vaccines - immunology
/ Vaccine
/ Vaccines
/ Vaccines, Synthetic - administration & dosage
/ Vaccines, Synthetic - chemistry
